![Ram Sasisekharan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ram Sasisekharan
Director/Board Member at Harvard Mit Health Sciences & Technology
Ram Sasisekharan active positions
Companies | Position | Start | End |
---|---|---|---|
Massachusetts Institute of Technology | Corporate Officer/Principal | 01/01/1996 | - |
Harvard Mit Health Sciences & Technology | Director/Board Member | 10/01/2011 | - |
Corporate Officer/Principal | - | - | |
David H. Koch Institute for Integrative Cancer Research
![]() David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Career history of Ram Sasisekharan
Former positions of Ram Sasisekharan
Companies | Position | Start | End |
---|---|---|---|
Cerulean Pharma, Inc.
![]() Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Director/Board Member | 01/10/2006 | 26/06/2015 |
Founder | 13/09/2011 | 26/06/2015 | |
Independent Dir/Board Member | 01/10/2006 | 26/06/2015 | |
MOMENTA PHARMACEUTICALS, INC. | Director/Board Member | 10/09/2010 | 10/09/2010 |
Founder | 01/05/2001 | 10/09/2010 | |
Tychan Pte Ltd.
![]() Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Founder | - | - |
VISTERRA INC | Founder | 20/12/2007 | - |
Training of Ram Sasisekharan
Harvard University | Graduate Degree |
University of Bangalore | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Statistics
International
United States | 9 |
India | 2 |
Singapore | 2 |
Operational
Founder | 4 |
Corporate Officer/Principal | 3 |
Director/Board Member | 3 |
Sectoral
Consumer Services | 5 |
Health Technology | 5 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 5 |
---|---|
Cerulean Pharma, Inc.
![]() Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
![]() Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Visterra, Inc.
![]() Visterra, Inc. Pharmaceuticals: MajorHealth Technology Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA. | Health Technology |
David H. Koch Institute for Integrative Cancer Research
![]() David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | Commercial Services |
Tychan Pte Ltd.
![]() Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Health Technology |
- Stock Market
- Insiders
- Ram Sasisekharan
- Experience